Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bacillus licheniformis is a probiotic bacterium that has been studied as an alternative or adjunct to traditional antibiotics, particularly in animal health (e.g., poultry, swine), and increasingly in human gut health. The scientific rationale is based on its ability to produce antimicrobial substances such as bacteriocins, lipopeptides, and enzymes that inhibit pathogenic bacteria like Salmonella, Escherichia coli, and Clostridium perfringens. Several animal studies and in vitro experiments have demonstrated that supplementation with B. licheniformis can reduce pathogen load, enhance gut barrier function, and modulate immune responses, leading to improved health and reduced need for antibiotic interventions.

However, while these results are promising, robust clinical evidence in humans is relatively limited. Some randomized controlled trials and systematic reviews in animals support the use of B. licheniformis as an effective alternative to antibiotics for promoting growth and preventing infections. In humans, a few studies suggest possible benefits in gut health and infection control, but large-scale, high-quality trials are lacking. Thus, the evidence is moderate (rated 3/5), with most studies being preclinical or in animal models. Its use as an antibiotic alternative is scientifically plausible and partially validated, but further research in human populations is warranted to confirm efficacy and safety.

More about Bacillus licheniformis
More about Antibiotics (alternatives to)

Other ingredients used for Antibiotics (alternatives to)

Other health conditions supported by Bacillus licheniformis

Products containing Bacillus licheniformis